NPC 15669

Drug Profile

NPC 15669

Latest Information Update: 24 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Class Anti-inflammatories; Antiplatelets; Antirheumatics; Branched-chain amino acids; Small molecules
  • Mechanism of Action Immunosuppressants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Myocardial ischaemia; Rheumatic disorders; Thrombosis; Ulcerative colitis
  • Discontinued Atherosclerosis; Transplant rejection

Most Recent Events

  • 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
  • 18 Dec 1996 Preclinical development for Myocardial ischaemia in USA (IV)
  • 18 Dec 1996 Preclinical development for Thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top